Resistance to second-line antibiotics, such as erythromycin and clindamycin, remains high amongst GBS, with several countries noting increased resistance rates in recent
The prevalence of resistance among GBS isolates was nearly twice as high among Caucasian women (44%) compared to African-American (24%) or Hispanic
The GBS resistance to erythromycin and clindamycin was 26
The proportion of isolates resistant to
Source: National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases
If such severe allergic history is present, GBS isolates should be tested for clindamycin susceptibility [ 1, 3 ]
In July 2019, the American Academy of Pediatrics (AAP) published a new clinical report— Management of Infants at Risk for Group B Streptococcal Disease
Group B Streptococcus (GBS) is a leading cause of neonatal infection, affecting 0
Group B Streptococcus (group B strep, GBS) emerged in the 1970s as the most common cause of sepsis in newborns
Although data suggesting that clinical failures are likely to occur in MLSBi streptococcal infections are lacking, by extension, the NCCLS has recommended performance of D
2021 Sep;21(9):1208-1209
Learn more about the CDC Streptococcus Laboratory and its epidemiologic and reference services
Because of increasing resistance to clindamycin and erythromycin, vancomycin is now the agent of choice for pregnant women with high-risk penicillin allergy
In reports from the ABCs from 2016, authors found that 42% of GBS isolates were resistant to clindamycin and 54% were resistant to erythromycin
Group B Streptococcus (GBS) is a major cause of neonatal morbidity and mortality C
In vitro resistance to macrolides and clindamycin by Group B Streptococcus isolated from pregnant and non pregnant women
Clindamycin and erythromycin resistance rates among Group B Streptococcus isolates by year
2020 Feb 13;2020:4048610
Guidelines recommend intrapartum antibiotic prophylaxis (IAP) for parturient women who have a screen positive for group B Streptococcus (GBS)
Intrapartum antibiotic prophylaxis (IAP) prevents neonatal mortality from Group B Streptococcus (GBS)